Seven studies were included in the review. Two RCTs (n=333) and one placebo-controlled trial (n=200) evaluated prophylaxis in children; two RCTs (n=54) evaluated treatment in children; and two RCTs (n=242) evaluated prophylaxis in the elderly.
One RCT scored 3 on the Jadad scale, three RCTs scored 2 and one study scored 0. Amantadine for prophylaxis in children.
One placebo-controlled trial (169 children analysed) and one RCT (234 children analysed) found that the occurrence of laboratory-confirmed influenza was significantly lower in those given amantadine prophylaxis compared with control: 32% with control versus 9.5% with amantadine (P<0.01) and 9% with control versus 2.9% with amantadine (P<0.01), respectively. One RCT (n=40), which was reported only in abstract format, presented insufficient information to determine the occurrence of laboratory-confirmed influenza according to treatment.
Amantadine for treatment in children (the results were presented only for children with laboratory-confirmed influenza).
One study (n=54) found that amantadine reduced the duration of fever compared with placebo: 1.48 days (standard deviation, SD=1.36) versus 2.64 days (SD=2.07). However, no difference was found in the numbers of symptoms (data not provided). The other study (n=50) also found that amantadine reduced the duration of fever compared with placebo: 0.63 days (SD=1.00) versus 1.10 days (SD=1.02).
Amantadine for prophylaxis in the elderly.
One study (54 participants analysed) found that the occurrence of laboratory-confirmed influenza and clinical influenza were lower in those given amantadine prophylaxis compared with control: 24% versus 38% and 28% versus 38%, respectively. The other study (178 participants analysed) found no cases of influenza during the study period.
There were no studies examining amantadine treatment in the elderly.